Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare's reimbursement policy

被引:6
作者
Li, Minghui [1 ]
Schulz, Richard [2 ]
Chisholm-Burns, Marie [1 ]
Wang, Junling [1 ]
Lu, Z. Kevin [2 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Memphis, TN USA
[2] Univ South Carolina, Coll Pharm, Columbia, SC 29208 USA
关键词
CLINICAL-PRACTICE GUIDELINE; NATIONAL COVERAGE DETERMINATION; CHEMOTHERAPY-INDUCED ANEMIA; CELL LUNG-CANCER; DOUBLE-BLIND; EPOETIN-ALPHA; DARBEPOETIN-ALPHA; AMERICAN-SOCIETY; SAFETY; ONCOLOGY;
D O I
10.18553/jmcp.2020.26.11.1477
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Because of increasing safety concerns related to erythropoiesis-stimulating agents (ESAs), the Centers for Medicare & Medicaid Services issued a Medicare reimbursement policy change regarding these medications in cancer patients. However, the policy established an absolute hemoglobin or hematocrit threshold to qualify for reasonable use but did not take the effect of gender and racial/ethnic differences in hemoglobin levels into consideration. OBJECTIVE: To examine disparities in the use of ESAs and blood transfusions after the Medicare policy change. METHODS: This study was an exploratory treatment effectiveness study and used the SEER-Medicare linked database. The treatment group was composed of cancer patients, whereas the control group was composed of chronic kidney disease patients. An interrupted time series design was used to examine the effect of the Medicare policy change on the use of ESAs and blood transfusions in different gender and racial/ethnic groups. RESULTS: The Medicare reimbursement policy change had an immediate effect on reducing the use of ESAs by 50% and increasing the use of blood transfusions by 10%. The immediate effect of the policy change on the monthly utilization of ESAs was 2 times greater in females (60% reduction) than males (30% reduction). Females had a 10% immediate increase in the monthly utilization of blood transfusions after the policy change. The policy change had the same immediate effect of a 50% reduction on the use of ESAs for Whites, African Americans/Blacks, and Latinos. African Americans/Blacks had a 50% immediate increase in the monthly utilization of blood transfusions after the policy change. CONCLUSIONS: Gender and racial/ethnic disparities were associated with the Medicare reimbursement policy change in the use of ESAs and blood transfusions. Thus, future policy considerations should keep biologic differences across gender and racial/ethnic groups in mind.
引用
收藏
页码:1477 / 1486
页数:10
相关论文
共 45 条
  • [21] KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
    Kliger, Alan S.
    Foley, Robert N.
    Goldfarb, David S.
    Goldstein, Stuart L.
    Johansen, Kirsten
    Singh, Ajay
    Szczech, Lynda
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 62 (05) : 849 - 859
  • [22] The Prevalence of Anemia and Moderate-Severe Anemia in the US Population (NHANES 2003-2012)
    Le, Chi Huu Hong
    [J]. PLOS ONE, 2016, 11 (11):
  • [23] Levin A, 2007, AM J KIDNEY DIS, V50, P471
  • [24] KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease - Foreword
    Levin, Adeera
    Rocco, Michael
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (05) : S9 - S145
  • [25] Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
    Leyland-Jones, B
    Semiglazov, V
    Pawlicki, M
    Pienkowski, T
    Tjulandin, S
    Manikhas, G
    Makhson, A
    Roth, A
    Dodwell, D
    Baselga, J
    Biakhov, M
    Valuckas, K
    Voznyi, E
    Liu, XY
    Vercammen, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5960 - 5972
  • [26] Breast cancer trial with erythropoietin terminated unexpectedly
    Leyland-Jones, B
    [J]. LANCET ONCOLOGY, 2003, 4 (08) : 459 - 460
  • [27] The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A US Health Plan Claims Database Study
    Major, Jacqueline M.
    Zhou, Esther H.
    Ding, Yulan
    Ly, Thomas
    Li, Jie
    Pinheiro, Simone P.
    Seymour, Sally
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07) : 700 - 709
  • [28] Use of epoetin and darbepoetin in patients with cancer: 2007 American society of clinical oncology/American society of hematology clinical practice guideline update
    Rizzo, J. Douglas
    Somerfield, Mark R.
    Hagerty, Karen L.
    Seidenfeld, Jerome
    Bohlius, Julia
    Bennett, Charles L.
    Cella, David F.
    Djulbegovic, Benjamin
    Goode, Matthew J.
    Jakubowski, Ann A.
    Rarick, Mark U.
    Regan, David H.
    Lichtin, Alan E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 132 - 149
  • [29] American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer
    Rizzo, J. Douglas
    Brouwers, Melissa
    Hurley, Patricia
    Seidenfeld, Jerome
    Somerfield, Mark R.
    Temin, Sarah
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2010, 6 (06) : 317 - U6
  • [30] Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    Rizzo, JD
    Lichtin, AE
    Woolf, SH
    Seidenfeld, J
    Bennett, CL
    Cella, D
    Djulbegovic, B
    Goode, MJ
    Jakubowski, AA
    Lee, SJ
    Miller, CB
    Rarick, MU
    Regan, DH
    Browman, GP
    Gordon, MS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) : 4083 - 4107